Sangamo BioSciences | SGMO - Ebitda


Sangamo BioSciences reported $-67.97M in EBITDA for its fiscal quarter ending in June of 2023.





Ebitda Change Date
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
Alterity Therapeutics Limited AUD -7.72M 2.99M Jun/2023
Amgen USD 5.8B 1.25B Sep/2026
Bayer EUR 1.62B 529M Sep/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Biogen USD 450.8M 198.9M Jun/2026
BioMarin Pharmaceutical USD 54.32M 167.99M Sep/2026
Cipla INR 13.88B 154.2M Sep/2026
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -8.84M 180K Jun/2026
CSL USD 3.13B 1.17B Dec/2025
Gilead Sciences USD -9.31B 12.82B Jun/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Grifols EUR 482.04M 7.04M Sep/2025
Ionis Pharmaceuticals USD -95.22M 9.99M Sep/2026
J&J USD 8.99B 721M Jun/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Merck USD 1.42B 2.97B Jun/2026
Novartis USD 8.62B 2.14B Sep/2026
Omeros USD -47.96M 7.39M Sep/2023
Pfizer USD 6.36B 350M Sep/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sanofi EUR 5.79B 2.1B Sep/2026
Sarepta Therapeutics USD -3.14M 33.31M Sep/2026
Tectonic Therapeutic USD -21.18M 365K Dec/2025
Ultragenyx Pharmaceutical USD -61M 94M Jun/2026
Vertex Pharmaceuticals USD 888.6M 436.6M Sep/2026